Hoth Therapeutics(HOTH.US)

Company Encyclopedia
View More
name
Hoth Therapeutics
HOTH.US
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer’s or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.
4.707 T
HOTH.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    14:00 ET Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program

    Hoth Therapeutics issued a comprehensive update on its therapeutic pipeline, highlighting progress in HT-001, HT-KIT, HT-ALZ, and a new GDNF-based metabolic program. Key developments include advancing clinical trials, FDA Orphan Drug Designation for HT-KIT, and collaborations with institutions like the Atlanta VA Medical Center. Upcoming milestones involve clinical data updates and regulatory submissions. CEO Robb Knie emphasized the focused and well-positioned pipeline targeting significant medical markets.

    prnewswire·
    US
    HOTH
    -1.30%
    prnewswire·
    US
    HOTH
    -1.30%

    Hoth Therapeutics Advances Phase 2 Trial of HT-001 for EGFR-Inhibitor-Associated Rash

    Hoth Therapeutics Inc. is advancing its Phase 2 CLEER-001 clinical trial of HT-001 for EGFR-inhibitor-associated rash in oncology supportive care. The company also progresses its HT-KIT program for mast cell diseases, nearing IND-enabling toxicology study completion. Clinical data updates are expected as enrollment continues, with an IND filing planned. This AI-generated news brief is for informational purposes only and not financial advice.

    Reuters·
    US
    HOTH
    -1.30%
    Reuters·
    US
    HOTH
    -1.30%

    Hoth Therapeutics to Present at Noble Capital Markets Emerging Growth Equity Conference

    Hoth Therapeutics, Inc. will present at the Noble Capital Markets 21st Annual Emerging Growth Equity Conference in Boca Raton, FL on December 2-3, 2025. CEO Robb Knie will represent the company, which focuses on small and microcap companies. The news was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    HOTH
    -1.30%
    Reuters·
    US
    HOTH
    -1.30%

    Hoth Therapeutics Accepted Into Nvidia Connect Program, Expanding Its Ai And Accelerated Computing Capabilities

    Hoth Therapeutics Inc:* HOTH THERAPEUTICS ACCEPTED INTO NVIDIA CONNECT PROGRAM, EXPANDING ITS AI AND ACCELERATED COMPUTING CAPABILITIES Source text: Further company coverage:

    Reuters·
    US
    HOTH
    -1.30%
    Reuters·
    US
    HOTH
    -1.30%

    Hoth Therapeutics shares are trading higher after the company was accepted into the NVIDIA Connect program to expand its AI and accelerated computing capabilities.

    benzinga_article·
    US
    HOTH
    -1.30%
    benzinga_article·
    US
    HOTH
    -1.30%
    © 2025 Longbridge｜Disclaimer